[{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia Therapeutics \/ Hermann-Texas Medical Center"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Praliciguat","moa":"sGC","graph1":"Nephrology","graph2":"Phase II","graph3":"Akebia Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.11,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Vadadustat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"}]
Find Clinical Drug Pipeline Developments & Deals by Akebia Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
